Naslov
Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

Autori
Steg, Philippe Gabriel ; Szarek, Michael ; Bhatt, Deepak L. ; Bittner, Vera A. ; Brégeault, Marie-France ; Dalby, Anthony J. ; Diaz, Rafael ; Edelberg, Jay M. ; Goodman, Shaun G. ; Hanotin, Corinne ; Harrington, Robert A. ; Jukema, J. Wouter ; Lecorps, Guillaume ; Mahaffey, Kenneth W. ; Moryusef, Angèle ; Ostadal, Petr ; Parkhomenko, Alexander ; Pordy, Robert ; Roe, Matthew T. ; Tricoci, Pierluigi ; Vogel, Robert ; White, Harvey D. ; Zeiher, Andreas M. ; Schwartz, Gregory G. ; For the ODYSSEY OUTCOMES Committees and Investigators†

Izvornik
Circulation (0009-7322) 140 (2019), 2; 103-112

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
acute coronary syndrome ; alirocumab ; cholesterol ; mortality ; PCSK9 protein

Sažetak
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double- blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85 ; 95% CI, 0.73 to 0.98 ; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%] ; HR, 0.88 ; 95% CI, 0.74 to 1.05 ; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%] ; HR, 0.77 ; 95% CI, 0.59 to 1.01 ; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for >= 3 years follow-up, alirocumab reduced death (HR, 0.78 ; 95% CI, 0.65 to 0.94 ; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C >= 100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71 ; 95% CI, 0.56 to 0.90 ; P- interaction=0.007). In the alirocumab group, all-cause death declined with achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for >= 3 years, if baseline LDL-C is >= 100 mg/dL, or if achieved LDL-C is low.

Izvorni jezik
Engleski

POVEZANOST RADA